Login to Your Account



Financings Roundup

Durata Completes $68M IPO; Prices Below Target Range

By Peter Winter
BioWorld Insight Editor

Wednesday, August 8, 2012

Further evidence that the post-Facebook initial public offering (IPO) jitters seem to have dissipated, and that the environment for biotech IPOs continues to improve comes with Thursday's debut of venture-backed Durata Therapeutics Inc., of Morristown, N.J. The company priced its initial public offering of 7.5 million shares of common stock at a price of $9 per share.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription